Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)Defense World · Sep 21, 2026
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional SharesBusiness Wire · Sep 14, 2026
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public OfferingBusiness Wire · Sep 10, 2026
Yarrow Bioscience Announces Proposed Underwritten Public OfferingBusiness Wire · Sep 10, 2026
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire · Aug 13, 2026
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye DiseaseBusiness Wire · Jul 27, 2026Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$11.00 | -$2.14 | Beat |
| May 14, 2026 | -$9.00 | -$32.50 | Miss |
| Mar 12, 2026 | -$0.10 | -$2.50 | Miss |
| Nov 6, 2025 | -$0.19 | -$0.17 | Beat |
| Aug 14, 2025 | -$0.23 | -$6.50 | Miss |
| May 8, 2025 | -$0.29 | -$0.20 | Beat |